319 related articles for article (PubMed ID: 25721293)
1. Sulforaphane induces ROS mediated induction of NKG2D ligands in human cancer cell lines and enhances susceptibility to NK cell mediated lysis.
Amin PJ; Shankar BS
Life Sci; 2015 Apr; 126():19-27. PubMed ID: 25721293
[TBL] [Abstract][Full Text] [Related]
2. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.
Schilling D; Kühnel A; Tetzlaff F; Konrad S; Multhoff G
Cancer Immunol Immunother; 2015 May; 64(5):599-608. PubMed ID: 25854583
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
[TBL] [Abstract][Full Text] [Related]
4. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
Mei JZ; Guo KY; Wei HM; Song CY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
[TBL] [Abstract][Full Text] [Related]
5. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
[TBL] [Abstract][Full Text] [Related]
6. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis.
Zhang C; Wang Y; Zhou Z; Zhang J; Tian Z
Cancer Immunol Immunother; 2009 Aug; 58(8):1275-85. PubMed ID: 19139882
[TBL] [Abstract][Full Text] [Related]
7. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract][Full Text] [Related]
9. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.
Zingoni A; Cecere F; Vulpis E; Fionda C; Molfetta R; Soriani A; Petrucci MT; Ricciardi MR; Fuerst D; Amendola MG; Mytilineos J; Cerboni C; Paolini R; Cippitelli M; Santoni A
J Immunol; 2015 Jul; 195(2):736-48. PubMed ID: 26071561
[TBL] [Abstract][Full Text] [Related]
10. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
11. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
12. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
Bilotta MT; Abruzzese MP; Molfetta R; Scarno G; Fionda C; Zingoni A; Soriani A; Garofalo T; Petrucci MT; Ricciardi MR; Paolini R; Santoni A; Cippitelli M
FASEB J; 2019 Aug; 33(8):9489-9504. PubMed ID: 31125275
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 10 decreases MICA expression on melanoma cell surface.
Serrano AE; Menares-Castillo E; Garrido-Tapia M; Ribeiro CH; Hernández CJ; Mendoza-Naranjo A; Gatica-Andrades M; Valenzuela-Diaz R; Zúñiga R; López MN; Salazar-Onfray F; Aguillón JC; Molina MC
Immunol Cell Biol; 2011 Mar; 89(3):447-57. PubMed ID: 20714339
[TBL] [Abstract][Full Text] [Related]
14. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Nishioka T; Fukunaga S; Futani H; Okamura H; Terada N
Oncol Rep; 2010 Dec; 24(6):1621-7. PubMed ID: 21042760
[TBL] [Abstract][Full Text] [Related]
15. Diversity and characterization of polymorphic 5' promoter haplotypes of MICA and MICB genes.
Cox ST; Madrigal JA; Saudemont A
Tissue Antigens; 2014 Sep; 84(3):293-303. PubMed ID: 24962621
[TBL] [Abstract][Full Text] [Related]
16. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.
Shiraishi K; Mimura K; Kua LF; Koh V; Siang LK; Nakajima S; Fujii H; Shabbir A; Yong WP; So J; Takenoshita S; Kono K
J Gastroenterol; 2016 Dec; 51(12):1101-1111. PubMed ID: 27002316
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients.
Ribeiro CH; Kramm K; Gálvez-Jirón F; Pola V; Bustamante M; Contreras HR; Sabag A; Garrido-Tapia M; Hernández CJ; Zúñiga R; Collazo N; Sotelo PH; Morales C; Mercado L; Catalán D; Aguillón JC; Molina MC
Oncol Rep; 2016 Mar; 35(3):1309-17. PubMed ID: 26708143
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.
Xu X; Rao G; Gaffud MJ; Ding HG; Maki G; Klingemann HG; Groh V; Spies T; Caillat-Zucman S; Gattuso P; Plate J; Prinz RA
J Clin Endocrinol Metab; 2006 Jul; 91(7):2704-12. PubMed ID: 16621903
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.
Kato N; Tanaka J; Sugita J; Toubai T; Miura Y; Ibata M; Syono Y; Ota S; Kondo T; Asaka M; Imamura M
Leukemia; 2007 Oct; 21(10):2103-8. PubMed ID: 17625602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
